alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THERMO
BIOANALYSIS CORPORATION'S QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED
APRIL 4, 1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-02-1999
<PERIOD-END>                               APR-04-1998
<CASH>                                          43,526
<SECURITIES>                                         0
<RECEIVABLES>                                   51,072
<ALLOWANCES>                                     5,926
<INVENTORY>                                     39,282
<CURRENT-ASSETS>                               141,875
<PP&E>                                          35,274
<DEPRECIATION>                                  13,114
<TOTAL-ASSETS>                                 324,866
<CURRENT-LIABILITIES>                           88,903
<BONDS>                                            198
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           141
<OTHER-SE>                                     135,485
<TOTAL-LIABILITY-AND-EQUITY>                   324,866
<SALES>                                         54,434
<TOTAL-REVENUES>                                54,434
<CGS>                                           26,583
<TOTAL-COSTS>                                   26,583
<OTHER-EXPENSES>                                 3,923
<LOSS-PROVISION>                                     5
<INTEREST-EXPENSE>                               2,003
<INCOME-PRETAX>                                  5,024
<INCOME-TAX>                                     1,822
<INCOME-CONTINUING>                              3,202
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,202
<EPS-PRIMARY>                                      .23
<EPS-DILUTED>                                      .21
        

</TABLE>
<PAGE> 1

Letter Re:  Unaudited Interim Financial Information
___________________________________________________

Aetna Inc.
Hartford, Connecticut

Ladies and Gentlemen:

Re:  Registration Statements No. 333-07167, 333-07169, 33-52819, 
33-52819-01, 333-08427, 333-08429, 333-08431 and 333-05791


With respect to the subject registration statements, we 
acknowledge our awareness of the use therein of our report dated 
November 3, 1997 related to our review of interim financial 
information.

Pursuant to Rule 436(c) under the Securities Act of 1933, such 
report is not considered a part of a registration statement 
prepared or certified by an accountant or a report prepared or 
certified by an accountant within the meaning of Sections 7 and 11 
of the Act.




                             By   /s/  KPMG PEAT MARWICK LLP  
                                 _____________________________
                                         (Signature)
                                       KPMG Peat Marwick LLP

Hartford, Connecticut
November 3, 1997
EXHIBIT 31.1

                                 CERTIFICATION

I, Vincent Vellardita, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Valcom, Inc. for the
quarter ended June 30, 2006;

2. Based on my knowledge, this report does not contain any untrue  statement of
a  material  fact  or  omit  to  state  a  material  fact necessary to make the
statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this report;

3.  Based  on  my  knowledge,  the  financial statements, and  other  financial
information included in this report,  fairly  present  in all material respects
the  financial condition, results of operations and cash  flows  of  the  small
business issuer as of, and for, the periods presented in this report;

4.  The   small  business  issuer's  other  certifying  officer(s)  and  I  are
responsible for establishing and maintaining disclosure controls and procedures
(as defined  in  Exchange  Act  Rules  13a-15(e)  and  15d-15(e)) for the small
business issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision,  to  ensure  that
material  information  relating  to  the  small  business issuer, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

(b)  Evaluated  the  effectiveness  of the small business  issuer's  disclosure
controls and procedures and presented  in this report our conclusions about the
effectiveness of the disclosure controls  and  procedures, as of the end of the
period covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the small business issuer's internal
control  over  financial  reporting  that occurred during  the  small  business
issuer's most recent fiscal quarter (the  small business issuer's fourth fiscal
quarter in the case of an annual report) that  has  materially  affected, or is
reasonably  likely  to materially affect, the small business issuer's  internal
control over financial reporting; and

5.  The  small  business  issuer's  other  certifying  officer(s)  and  I  have
disclosed, based  on  our  most  recent  evaluation  of  internal  control over
financial  reporting,  to  the  small business issuer's auditors and the  audit
committee  of  the  small business issuer's  board  of  directors  (or  persons
performing the equivalent functions):

(a) All significant deficiencies  and  material  weaknesses  in  the  design or
operation  of  internal  control  over financial reporting which are reasonably
likely  to adversely affect the small  business  issuer's  ability  to  record,
process, summarize and report financial information; and

(b) Any fraud,  whether  or  not  material,  that  involves management or other
employees who have a significant role in the small business  issuer's  internal
control over financial reporting.

August 21, 2006


/s/ Vincent Vellardita
---------------------------
Vincent Vellardita
Chief Executive Officer
-82 -80 -78 -76 -74 -72

36 38 40 

### ★

▲ ▲ ▲ ▲



### ★ ▲ ▲ ▲ ▲ 500 1000 1500 500 18 12 06 00 06/19 

### NOAA HYSPLIT MODEL 

## Backward trajectory ending at 2300 UTC 19 Jun 07

EDAS Meteorological DataSource★at 39.41 N 76.30 WMeters AGL
##### 



Exhibit 99.3

Chief Financial Officers Certification required under Section 906 of
Sarbanes-Oxley Act of 2002

In connection with the quarterly report of TIB Financial Corp. (the Company)
on Form 10-Q for the period ended June 30, 2002, as filed with the Securities
and Exchange Commission (the Report), I, David P. Johnson, Executive Vice
President and Chief Financial Officer of the Company, certify pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that this Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934 and that, to my knowledge, the information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operation of the Company.

|      |  |                   |  |                                                                      
|----- |  | ----------------- |  | ---------------------------------------------------------------------
|Date: |  | November 14, 2002 |  | /s/ David P. Johnson                                                 
|      |  |                   |  |                                                                      
|      |  |                   |  | David P. Johnson
Executive Vice President and Chief Financial Officer

27
Exhibit 32.1
                                                                    ------------





               Commodore Applied Technologies, Inc. & Subsidiaries
                    Certification Of Chief Executive Officer
           Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To
                  Section 906 Of The Sarbanes-Oxley Act Of 2002



In connection with the quarterly report of Commodore Applied Technologies,  Inc.
(the "Company") on form 10-Q for the three and six-month  periods ended June 30,
2006,  Shelby Brewer hereby  certifies,  pursuant to 18 U.S.C.  Section 1350, as
adopted pursuant to section 906 of the  Sarbanes-Oxley  Act of 2002, that to the
best of his knowledge:

         (1)  The  quarterly  report fully  complies  with the  requirements  of
              section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)  The information contained in the quarterly report fairly presents,
              in all material  respects,  the financial  condition and result of
              operations of the Company.

Date:    August 21, 2006

/s/ Shelby T. Brewer
--------------------
Shelby T. Brewer
Chairman of the Board and Chief Executive Officer
Fourth Court of Appeals

San Antonio, Texas

September 30, 2015

No. 04-14-00338-CR

Benny Cavazos VALVERDE,

Appellant

v.

THE STATE OF TEXAS,

Appellee

From the 290th Judicial District Court, Bexar County, Texas

Trial Court No. 2012CR3980

Honorable Melisa Skinner, Judge Presiding

O R D E R

Appellee’s motion for extension of time to file brief is GRANTED. The appellee’s brief 

is due on October 30, 2015. 

_________________________________

Sandee Bryan Marion, Chief Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 30th day of September, 2015.

___________________________________

Keith E. Hottle

Clerk of Court
# C_2022151EN.01000401.xml

| 6.4.2022 | EN | Official Journal of the European Union | C 151/4 |
| --- | --- | --- | --- |

6.4.2022

EN

Official Journal of the European Union

C 151/4

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2022/C 151/04)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2022) 1518 | 17 March 2022 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Diagnostica Stago, 3 allée Thérésa, CS 10009, 92665, Asnières sur Seine, France | REACH/22/4/0 | Industrial use for its detergent properties in the process of cell lysing for the production of in-vitro diagnostic reagents (Asserachrom® HPIA, Asserachrom® HPIA–IgG and Asserachrom® PF4 and STA®-Néoplastine® R15 assays) | 4 January 2028 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies. |
| REACH/22/4/1 | Industrial use in view of controlling the amount of non-specific reactions in the production of in-vitro diagnostic reagents (STA® - Liatest® D-Di assays) | 4 January 2033 |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2022) 1518

17 March 2022

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Diagnostica Stago, 3 allée Thérésa, CS 10009, 92665, Asnières sur Seine, France

REACH/22/4/0

Industrial use for its detergent properties in the process of cell lysing for the production of in-vitro diagnostic reagents (Asserachrom® HPIA, Asserachrom® HPIA–IgG and Asserachrom® PF4 and STA®-Néoplastine® R15 assays)

4 January 2028

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies.

REACH/22/4/1

Industrial use in view of controlling the amount of non-specific reactions in the production of in-vitro diagnostic reagents (STA® - Liatest® D-Di assays)

4 January 2033

---

(1)  OJ L 396, 30.12.2006, p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu).

---
* Pursuant to 5 TH C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals

Fifth Circuit 

## FILED June 29, 2006 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 05-60892 Summary Calendar

RAHIBHAI SADRUDDIN MOMIN, Petitioner,

versus ALBERTO R. GONZALES, U.S. ATTORNEY GENERAL, Respondent.

-------------------- Petition for Review of an Order of the Board of Immigration Appeals BIA No. A95 215 262

-------------------- Before HIGGINBOTHAM, BENAVIDES, and DENNIS, Circuit Judges.
PER CURIAM: * Rahibhai Sadruddin Momin (Momin), a native and citizen of India, petitions for review of the order of the Board of Immigration Appeals (BIA) adopting and affirming the immigration judge’s (IJ) decision denying his application for withholding of removal, relief under the Convention Against Torture Act (the CAT Act), and voluntary departure. We will uphold findings that an alien is not eligible for withholding of removal or protection under the CAT Act if the findings are supported by substantial evidence. Efe v. Ashcroft , 293 F.3d 899, 906 (5th Cir. 2002).No. 05-60892 -2- Under the substantial evidence standard, reversal of the BIA’s decision is improper unless the alien shows that the evidence compels it. Majd v. Gonzales , ___ F.3d ___, 2006 WL 990740, *3 (5th Cir. Apr. 17, 2006) (No. 05-60141). Our review of the record reveals there is substantial evidence to support the IJ’s rulings that: (1) Momin did not suffer past persecution; and (2) he has not shown that it is more likely than not he will suffer persecution or torture if he is returned to India. See 8 C.F.R. § 208.16(c)(3); Eduard v. Ashcroft , 379 F.3d 182, 187 n.4, 188 (5th Cir. 2004). Moreover, Momin has not shown that the evidence compels a reversal of the decision. Additionally, Momin does not challenge the denial of his request for voluntary departure. Accordingly, this issue is deemed abandoned. Calderon-Ontiveros v. INS , 809 F.2d 1050, 1052 (5th Cir. 1986). Momin’s petition for review is therefore DENIED.
Exhibit
32.1








Chief
Executive Officer’s Certification required under Section 906 of Sarbanes-Oxley
Act of 2002





In
connection with the quarterly report of TIB Financial Corp. (the “Company”) on
Form 10-Q for the period ended June 30, 2008, as filed with the Securities and
Exchange Commission (the “Report”), I, Thomas J. Longe, Chairman and Chief
Executive Officer of the Company, certify pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that this Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and that, to my knowledge, the information contained in the Report fairly
presents, in all material respects, the financial condition and results of
operation of the Company.








Date:           August
      11, 2008
            /s/
      Thomas J. LongeThomas
      J. Longe
              Chairman
      and Chief Executive Officer











A signed
original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written statement required
by Section 906, has been provided to TIB Financial Corp. and will be retained by
TIB Financial Corp. and furnished to the Securities and Exchange Commission or
its staff upon request.
Exhibit 32.2








Chief Financial Officer’s Certification required under Section 906 of Sarbanes-Oxley Act of 2002





In connection with the quarterly report of TIB Financial Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2010, as filed with the Securities and Exchange Commission (the “Report”), I, Stephen J. Gilhooly, Executive Vice President and Chief Financial Officer of the Company, certify pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that, to my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.








Date:           May 14, 2010
/s/ Stephen J. GilhoolyStephen J. Gilhooly

Executive Vice President, Chief Financial Officer and Treasurer











A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to TIB Financial Corp. and will be retained by TIB Financial Corp. and furnished to the Securities and Exchange Commission or its staff upon request.
### INDIANA DEPARTMENT OF ENVIRONMENTAL MANAGEMENT We ProtectHoosiers and Our Environment. 100 N. Senate Avenue • Indianapolis, IN 46204 (800) 451-6027 • (317) 232-8603 • www.idem.IN.gov Michael R. Pence Govemor

Susan Hedman Regional Administrator U.S. EPA, Region 5 77 West Jackson Boulevard Chicago, Illinois 60604

Dear Ms. Hedman: 

### January 

### 26, 2015 Thomas W. Easterly Commissioner

Re: State Implementation Plan Submittal for Indiana Regarding 326 lAC 2-7-10.5 and 326 lAC 2-8-11.1, MinorNew Source Review for Title V and FESOP Sources (LSA #11-747); Supplement (LSA #13- 534(AC))

On November 7, 2013, IDEM submitted an amendment to the Indiana state implementation plan (SIP) for 326 lAC 2-7-10.5 and 326 lAC 2-8-11.1 concerning minor new source review. An agency correctionwas filed withtheIndianaRegister for this rule onNovember**·~7,** 2013. The following document is enclosed: Agency Correction: LSA Document #l3-534(AC) as published inthe IndianaRegister on December 25, 2013 (DIN: 20131225-IR-326130534ACA). This submittal consists ofone (1) hard copy ofthe required documentation. An electronic version ofthe submittal in PDF fmmat that is identical to the hard copyhas been sent to Chris Panos atthe U.S. EPA Region 5 office. I request thatU.S. EPA approve this modification ofIndiana's stateimplementation plan. 

### Ifyou have any questions regarding this submittal, please contact Christine Pedersen, Rule Development Section Chief, Office ofLegal Counsel at (317) 233-5684.

KB/sb Enclosure

cc: SamPmtanova, U.S. EPA RegionV SIP file

An Equal Opportunity Employer Sincerely,

# ~~~r Keith Baugues Assistant Commissioner Office ofAir Quality 

# 0

AStatethatWorks 

# - @RecycledPaperIndiana Register TITLE 326 AIR POLLUTION CONTROL DIVISION Agency Correction LSA Document #13-534(AC) Under IC 4-22-2-38, corrects the following typographical, clerical, or spelling errors in the Indiana Administrative Code: (1) In 3261AC 2-7-10.5(f)(2)(C), add"," after "standards". (2) In 326 lAC 2-7-10.5(f)(2)(C), add"," after "subsection (g)". (3) In 326 lAC 2-8-11.1 (d)(4), delete "clause (E)" and insert "subdivision (5)". Filed with Publisher: November27, 2013, 12:51 p.m. Under IC 4-22-2-38(g)(2), this correction takes effect 45 days from the da.te and time filed with the Publisher. Posted: 12/25/2013 byLegislative Services Agency An html version ofthis document.

Date: Jan 23,2015 8:55:13AM EST DIN: 20131225-IR-326130534ACA Page 1
[Federal Register Volume 89, Number 186 (Wednesday, September 25, 2024)]
[Notices]
[Pages 78320-78321]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21860]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as

[[Page 78321]]

amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Investigator Initiated 
Program Project Applications (P01 Clinical Trial Not Allowed).
    Date: November 4, 2024.
    Time: 10:00 a.m. to 2:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F21B, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F21B, 
Rockville, MD 20892, 240-669-5026, <a href="/cdn-cgi/l/email-protection#533b32213a213a3e35133d3a323a377d3d3a3b7d343c25"><span class="__cf_email__" data-cfemail="ec848d9e859e85818aac82858d8588c2828584c28b839a">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

     Dated: September 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21860 Filed 9-24-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>